DAFTAR PUSTAKA
1. World Health Organization. Global tuberculosis report 2012. Geneva; WHO Press; 2012: 9-11, 115
2. World Health Organization. Global tuberculosis report 2011. Geneva; WHO Press ;2011: 3
3. Blanc L, Falzon D, Fitzpatrick C et al. In: Global tuberculosis control 2010. Geneva; WHO Press; 2010: 5-7
4. Perhimpunan Dokter Paru Indonesia, Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Jakarta: Indah Offset Citra Grafika; 2011: 1-21
5. Utarini A, Wuryaningtyas B, Basri C, Strategi Nasional Pengendalian TB di Indonesia 2010-2014. Mustikawati DE, Surya A, editor. Jakarta: Kementerian Kesehatan Republik Indonesia Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan 2011
6. Wright A, Zignol M. Anti-Tuberculosis Drug Resistance in The World. Fourth Global Report. Wright A, Zignol M, Dye C.etds. Geneva: WHO; 2008: 25
7. Global Tuberculosis control WHO Report 2009. Tuberculosis Profile : Indonesia. Available from
8. Sihombing Hendra. Pola Resistensi Primer pada Penderita TB Paru Kategori I di RSUPH Adam Malik Medan [tesis] Medan: departemen Pulmonologi dan Ilmu Kedokteran Respirasi Fakultas Kedokteran Universitas Sumatera Utara; 2011
9. Lodenkemper Loddenkemper R, Sagebiel D, Brendel A, Strategies Against Multidrug-Resistant Tuberculosis. Eur Respir J 2002; 20: (36): 66-77
10.Reichman LB, Tanne JH. Timebomb, The Global Epidemic of Multi-Drug-Resistant Tuberculosis. New York: McGraw-Hill; 2002:227
11.Munir SM, Nawas A, Soetoyo DK. Pengamatan Pasien Tuberkulosis Paru dengan Multidrug Resistant (TB-MDR) di Poliklinik Paru RSUP Persahabatan. J Respir Indo; 2010; 30 (20): 90-104
12.Kodrat. Pola Resistensi Mikobakterium Tuberkulosa di BP4 Medan. Departemen Pulmonologi dan Ilmu Kedokteran Respirasi Fakultas Kedokteran Universitas Sumatera Utara; 1998
14.Perhimpunan Dokter Paru Indonesia, Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Jakarta: Indah Offset Citra Grafika; 2006
15.Soepandi PZ, Diagnosis dan Faktor yang Mempengaruhi Terjadinya TB-MDR. Jakarta: Departemen Pulmonologi & Ilmu Kedokteran Respirasi FKUI-RS Persahabatan; 2008
16.Lestari S. H., Rintiswati N., Ng N. Pola Resistensi Kuman Mycobacterium tuberculosis Terhadap Obat Anti Tuberkulosis (OAT) di Propinsi Daerah Istimewa Yogyakarta: Sains Kesehatan. 2004
17.Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among persons with tuberculosis in California 1994-2003: JAMA 2005; 293: 22
18.Rintiswati N., Dwianingsih E.K., Rahman A. Resistensi Mycobacterium tuberculosis terhadap beberapa obat anti tuberculosis pilihan utama dan pilihan kedua di Laboratorium Mikrobiologi FK UGM Tahun 2000 – 2004: Berkala Ilmu Kedokteran. 2005
19.Rao N.A., Irfan M., Hussain S.J. Primary Drug Resistance Against Mycobacterium Tuberculosis in Karachi. Department of Medicine, Karachi, Pakistan, Aga Khan University; 2008:58(3):122-5.
20.Susi. Pola Resistensi Mycobacterium Tuberculosis pada Narapidana di Lembaga Permayarakatan Kelas I Pria Tanjung Gusta Medan Periode Juli – Desember 2007. Medan, Universitass Sumatera Utara; 2008
21.Munir S.M., Nawas A., Soetoyo D.K. Pengamatan Pasien Tuberkulosis Paru dengan Multidrug Resistant (TB-MDR) di Poliklinik Paru RSUP Persahabatan. Departemen Pulmonologi dan Ilmu Kedokteran Respirasi, Jakarta, Universitas Indonesia; 2010:30(2):92
22.Arifin Nawas, Dedi Nofizar, Erlina Burhan. Identifikasi Faktor Risiko Tuberkulosis Multidrug Resistant (TB-MDR). Maj Kedokteran Indonesia, Volum:60, Nomor: 12. 2010. 537-545.
23.Granich RM, Oh P, Lewis B, Porco TC, Flood J. Multidrug resistance among person with tuberculosis in California 1994-2003. JAMA. 2005; 293(22): 2732-9.
24.Mirsaedi SM et al. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. Available at
26.Philip MR et al. Characteristics of multidrug-resistant tuberculosis in Namibia. BMC Infectious Disease 2012, 12:385. Available at
27.Begum et al. Tuberculosis and patient gender in Bangladesh: sex differences in diagnosis and treatment outcome.
28.Edward et al. Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis. American Journal Respiratory Critical Care Medicine. Vol 169. 2004. Pp 1103-1109.
29.Hadiarto Mangunnegoro, Aditama T, Hudoyo A. Treatment of multidrug resistant tuberculosis in Indonesia. Chemotherapy. I 996;42(Supp13):24-9.
30.Fenton JM, Vermeulen WM, Immunopathology of Tuberculosis: Roles of Macrophages and Monocyte. American Society for Microbiology: 1996: 683-690
31.Wallace RJ, Griffith DE, Antymycobacterial Agents. Infectious Diseases. In: Harrison’s Principles of Internal Medicine. Fauci AS, Braunwald E, Kasper DL, et al edts. New York: Mc Graw Hill Medicine; 2008: 1032-6
32.Sukandar EY, Andrajati R, Sigit JI, Adnyana IK, Setiadi AAP, Kusnandar. ISO farmakoterapi. Jakarta: Ikatan Sarjana Farmasi Indonesia; 2009: 920
33.Katzung BG, Basic & Clinical Pharmacology 10thEdition. McGraw-Hill Companies Inc. Dalam terjemahan: Farmakologi Dasar & Klinik. Nirmala WK, Yesdelita N, Susanto D, Dany F. (edt). Jakarta: EGC, 2007:796-801
34.Tulak A, Hudoyo A, Aditama TY. Pengobatan TB-MDR dengan Ofloksasin. Jurnal Tuberkulosis Indonesia. Vol 4 no 3. Departemen Pulmonologi dan Ilmu Kedokteran Respirasi FK: UI-RS Persahabatan, Jakarta
35.Alsagaff H, Mukty A, Dasar-dasar ilmu penyakit paru, Cetakan ketujuh. Surabaya: Airlangga University Press; 2010
36.Aditama TY. Pengobatan tuberkulosis diagnosis terapi dan masalahnya. Jakarta: FKUI; 2002: 2-3
37.Santoso W, Akila MM, Widyastuti S, Nadia S, Kadarsih R, Karuniawati A dan kawan-kawan. Standar Reagen Zhiel Neelsen. Departemen Kesehatan Republik Indonesia. Jakarta Direktorat Jenderal Bina Pelayanan Medik-Direktorat Bina Pelayanan Penunjang Medik; 2008: 7-10
39.World Health Organization. Guidlines on Standard Operating Procedure for Microbiology. Available from
40.Sjahrurachman A, Modul Kultur dan Uji Kepekaan M. tuberculosis Terhadap Obat anti Tuberkulosis Lini Pertama. Jakarta: Departemen Kesehatan Republik Indonesia,2008
41.National Institute of Allergy and Infectious Diseases. Multidrug-Resistant Tuberculosis (TB-MDR) and Possible Treatments. U. S. Departement og Health and Human Services. National Institutes of Health. 2007. Available from
42.Bayona J, Caminero J, Coker R. Et al. Guidlines for The Programmatic Management of Drug-resistant Tuberculosis Emergency update 2008. Rich M, Jaramillo E, Keshavjee S,Edts. WHO, 2008: 3-8,60
43.Sharma SK, Mohan A. Multidrug-resistant tuberculosis. Indian J Med Res 120: Tirupati, India:2004: 354-376
44.Soedarsono. Multidrug-Resistant (MDR)-TB. Dalam: Buku Ajar Ilmu PenyakitParu 2010. Surabaya: Departemen Ilmu Penyakit Paru Fakultas Kedokteran Universitas Airlangga-RSUD Dr. Soetomo; 2010: 27-36
45.Kreider ME, Rossman MD. Clinical Presentation and Treatment of Tuberculosis. In; Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM. Pulmonary Disease and Disorders. Philadelphia. Mc Graw Hill.2000.2479-2480
46.Fordiastiko. Penatalaksanaan tuberkulosis paru pada penderita diabetes melitus. Paru 1995; 15: 105-10.
47.Rasmin M, Yunus F, Priyanti ZS, Melintira I, Puspitorini D, Rahayu S, Pratama S. Profil Penderita Tuberkulosis Paru Di Poli Paru RS Persahabatan Januari – Juli 2005. 2013. Available from :
48.Modul-3, Pengobatan. Pelatihan Penanggulangan TB MDR, Sub Direktorat Tuberkulosis, Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Departemen Kesehatan R.I, 2009.1-57
49.Handayani TN, Yudani MR, Hasim WA. Hubungan Tingkat Pengetahuan Penderita Multi Drug Resistant Tuberculosis (TB MDR) Dengan Prevalensinya di RS Paru Batu. Available at http://old.fk.ub.ac.id/artikel/id/ MajalahWahid%20Hasim%20Asari.pdf
51.GBC Health. Drug-Resitant TB: Why It Matters. Juli 2011. Available at
52.Saraswati et al. Household Contact of Pulmonary Tuberculosis in Wonogiri District,
Central Java Province, Indonesia. Available at
53.MMWR. Interstate Outbreak of Drug-Resistant Tuberculosis Involving Children --
California, Montana, Nevada, Utah. Availble at
54.Sharaf GSE et al. Tuberculosis in Sudan: a study of Mycobacterium tuberculosis strain genotype and susceptibility to anti-tuberculosis drugs. BMC Infectious Diseases 2011. Available at
55.Hirpa S et al. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study. BMC Public Health 2013. Available at
56.Available at
57.Coljin et al. Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis
before and during Therapy. 2011.
58.Fisher et al. Type 2 diabetes and multi-drug resistant tuberculosis. Scand J Infect Dis. 2008 ; 40(11-12): 888–893. Availble at PMC 2010 June 18.
59.Geerlings SE, Hoepelman AI. Immune Dysfunction in Patients With Diabetes Mellitus (DM). FEMS Immunol Med Microbiol 1999;26. 259-65.
60.Al-Attiyah RJ, Mustafa AS. Mycobacterial Antigen-Induced T helper type 1 (Th1) and Th2 Reactivity of Peripheral Blood Mononuclear Cells from Diabetic and Non-diabetic Tuberculosis Patients and Mycobacterium bovis bacilli Calmette–Guérin (BCG)-Vaccinated Healthy Subjects. Clin Exp Immunol. 2009 October; 158(1): 64– 73.
62.Ruddy M et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax 2005; 60. 130-135.
63.Brust JCM et al. Chest X-ray Findings in Patients with Multidrug-Resistance Tuberculosis and HIV Co-Infection in South Africa. Available at
64.Zahirifard et al. The Radiological Spectrum of Pulmonary Multidrug-Resistant Tuberculosis in HIV-Negative Patients. Iranian Journal of Radiology. 2003; 1(3-4). 161-166.
65.Francis JC. Tuberculosis Drug Information Guide. Available at
66.Goodman & Gilman’s. The Pharmacological Basis of Therapeutic. 11 edtion. New York: McGraw Hill. 1203-1221
67. Iseman MD. Treatment of Multidrug-Resistance Tuberculosis. New England Journal of Medicine. 1993. Vol.329.11.784-791.
68. Jain et al. Novel mutations in emb B gene of ethambutol resistant isolates of Mycobacterium tuberculosis: a preliminary repor Nov;128(5):634-9.
69. Sreevatsan et al. Ethambutol Resistance in Mycobacterium tuberculosis: Critical Role of embB Mutations. Antimicrobial Agents And Chemotherapy, Vol. 41, No. 8. 1997. 1677-1681.
70. Ali et al. Characterization of Mutations Conferring Extensive Drug Resistance to
Mycobacterium tuberculosis Isolates in Pakistan. Antimicrobial Agents And Chemotherapy, Vol. 55, No. 12. December, 2012. 5654-5659.
71. Maus et al. Mutation of tlyA Confers Capreomycin Resistance in Mycobacterium tuberculosis.Antimicrobial Agents And Chemotherapy, Vol. 49, No. 2. February, 2005. 571-577.
72. Wang et al. Prevalence of Multidrug and Extensively Drug-Resistant Tuberculosis in Beijing, China: a Hospital-Based Retrospective Study. Japan Journal of Infectious Disease. 63.2010.368-371.
